MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ
4.340
-0.010
-0.23%
After Hours: 4.399 +0.059 +1.37% 18:09 05/08 EDT
OPEN
4.340
PREV CLOSE
4.350
HIGH
4.400
LOW
4.309
VOLUME
752.85K
TURNOVER
--
52 WEEK HIGH
5.10
52 WEEK LOW
2.940
MARKET CAP
854.72M
P/E (TTM)
-24.8284
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ABUS last week (0427-0501)?
Weekly Report · 6d ago
UPDATE 2-Moderna tops revenue estimates on stronger international COVID vaccine sales
Reuters · 05/01 10:38
Moderna tops quarterly revenue estimates on stronger international COVID vaccine sales
Reuters · 05/01 10:30
Weekly Report: what happened at ABUS last week (0420-0424)?
Weekly Report · 04/27 10:21
Europe Clears First Flu/COVID Combo Shot From Moderna
Benzinga · 04/21 17:58
Weekly Report: what happened at ABUS last week (0413-0417)?
Weekly Report · 04/20 10:17
Moderna's Quarterly Earnings Preview: What You Need to Know
Barchart · 04/20 05:55
QuidelOrtho, MIND Technology, Southern First Bancshares And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Benzinga · 04/16 12:03
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Webull offers Arbutus Biopharma Corp stock information, including NASDAQ: ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.